Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Engineering × 1 year × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

pembrolizumab 1066 Specimen Handling 746 Carboplatin 700 Magnetic Resonance Spectroscopy 677 Cyclophosphamide 676 Cisplatin 600 Nivolumab 588 Paclitaxel 526 Radiotherapy 501 Gemcitabine 471 Biopsy 448 Bevacizumab 393 Dexamethasone 379 fludarabine 340 Docetaxel 335 venetoclax 329 atezolizumab 311 Oxaliplatin 304 Capecitabine 303 Fluorouracil 302 Rituximab 290 durvalumab 283 Drug Therapy 280 Radiosurgery 273 Pemetrexed 262 Standard of Care 262 Doxorubicin 259 Ipilimumab 259 Blood Specimen Collection 246 Radiation 245

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07366658 2026-01-26

NEUK203-13

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 1 Not yet recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡